INyX Pharma - Solutions for Respiratory, Allergy, Dermatological and Topical Conditions

INyX Pharma is a specialty pharmaceutical company that focuses its expertise on development-led contract manufacturing in the sterile pharmaceutical, finished dosage-form, outsourcing sector. INyX Pharma specialises in aerosol drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. With a growing array of sophisticated development and manufacturing capabilities, and the advent of many new macromolecule drugs that are inhaleable, there are increasing business opportunities for INyX's specialty pharmaceutical aerosol expertise.

STERILE FILL AND DRUG DELIVERY SYSTEMS

INyX is focused on pursuing strategic growth opportunities in a number of sectors within the pharmaceutical, biotechnology and medical devices industries. These include research and development, manufacturing, distribution and intellectual property acquisitions. Key acquisition targets include high-quality manufacturing operations that offer complementary services to our current sterile fill and drug delivery capabilities. Other essential assets include a strong customer base and excellent manufacturing and quality systems for rapid business ramp-up. By acquiring under-utilized but specialized and synergistic pharmaceutical manufacturing facilities with established client lists, we are able to effectively exploit niche pharmaceutical production capabilities for a wider customer base.

INyX's client base is comprised of blue-chip ethical pharmaceutical companies, branded generic firms and biotechnology groups. INyX manufactures for a majority of global markets, including: North America, Europe, Latin America and the Middle East.

PHARMACEUTICAL AEROSOL PRODUCTION

Our company's R&D and production operations are conducted through a wholly owned subsidiary, INyX Pharma Limited, which has a 60,000ft² manufacturing facility and a 15,000ft² laboratory site in Runcorn, near Manchester, England. These facilities are ISO 9001 accredited and are cGMP (current Good Manufacturing Practice) compliant with the United States Food and Drug Administration (FDA) and the Canadian and European Regulatory bodies. In fact, INyX is one of only three independent pharmaceutical companies to have FDA, Canadian and European regulatory approvals for pharmaceutical aerosol production.

AEROSOL DRUG DELIVERY TECHNOLOGY

Next year, the next phase of INyX's evolution will commence, which is to leverage our company's aerosol drug delivery technology to develop our own proprietary products. We already have strategic relationships in place with key clients for business-development support and we intend to use their pharmaceutical sales forces to market Inyx proprietary products in the dermatology, respiratory and allergy markets.